
Please try another search
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Edward W. Unkart | 71 | 2014 | Independent Director |
Brian J. G. Pereira | 63 | 2019 | Independent Chairman |
Benjamin L. Palleiko | 58 | 2016 | CEO & Director |
Tomas Kiselak | 37 | 2015 | Board Observer |
Nancy Stuart | 66 | 2021 | Independent Director |
Patrick A. Treanor | 56 | 2022 | Independent Director |
William Carl Fairey | 60 | 2024 | Independent Director |
Laurence E. Reid | 60 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review